The University of British Columbia
UBC - A Place of Mind
The University of British Columbia Okanagan campus
Institute for Healthy Living and Chronic Disease Prevention
  • Home
  • Participate in Research
  • About
  • Research
    • Research Cluster in Aging in Place
    • Research Cluster in Culture, Creativity, Health and Well-Being
    • Research Cluster in Homelessness
    • Research Cluster in Rural Health Equity
    • Research Cluster in Urban Indigenous Wellbeing
    • Healthy and successful aging
    • Chronic Disease Prevention
    • Completed Research
    • Featured Research
  • People
  • Opportunities
  • Events
    • Events-Calendar
    • Event History – 2023
    • Event History – 2022
    • Event History – 2021
    • Event History – 2020
    • Event History – 2019
    • Event History – 2018
    • Event History – 2017
    • Event History – 2016
    • Event History – 2015
  • News
  • Age Friendly University
  • Embrace Aging
  • Contact Us

Psychedelic mushroom microdoses can improve mood, mental health

Posted in Mental Health, Research News, UBC Okanagan News, Wellbeing on July 11, 2022

Seniors Daily Exercise

A new UBCO study finds people are using small doses of psychedelics not for recreational purposes, but to combat anxiety and depression.

The latest study to examine how tiny amounts of psychedelics can impact mental health provides further evidence of the therapeutic potential of microdosing.

Published in Nature-Scientific Reports this week, the study followed 953 people taking regular small amounts of psilocybin and a second group of 180 people that were not microdosing. This research, led by UBC Okanagan’s Dr. Zach Walsh and doctoral student Joseph Rootman is the latest study to come from the Microdose.me project.

For the 30-day study, participants were asked to complete a number of assessments that tap into mental health symptomology, mood and measures of cognition. For example, a smartphone finger tap test was integrated into the study to measure psychomotor ability, which can be used as a marker for neurodegenerative disorders including Parkinson’s disease.

Those microdosing demonstrated greater improvements in mood, mental health and psychomotor ability over the one-month period compared to non-microdosing peers who completed the same assessments.

“This is the largest longitudinal study of this kind to date of microdosing psilocybin and one of the few studies to engage a control group,” says Dr. Walsh, who teaches in the Irving K. Barber Faculty of Arts and Social Sciences. “Our findings of improved mood and reduced symptoms of depression, anxiety and stress add to the growing conversation about the therapeutic potential of microdosing.”

Read the full story here: UBC Okanagan News

← Previous Post Next Post →
Research NewsFeatured Research

Other Research

  • Research Cluster in Aging in Place
  • Research Cluster in Culture, Creativity, Health and Well-Being
  • Research Cluster in Homelessness
  • Research Cluster in Rural Health Equity
  • Research Cluster in Urban Indigenous Wellbeing
  • Healthy and successful aging
  • Chronic Disease Prevention
  • Campus Health
  • Completed Research

Posted in Mental Health, Research News, UBC Okanagan News, Wellbeing | Tagged microdose, microdosing, psilocybin

Institute for Healthy Living & Chronic Disease Prevention
Okanagan Campus
ART223 - 1147 Research Road
Kelowna, BC Canada V1V 1V7
Tel 250 807 8072
Email healthyliving.research@ubc.ca
Back to top
The University of British Columbia
  • Emergency Procedures |
  • Terms of Use |
  • Copyright |
  • Accessibility
X